Kazia Therapeutics Ltd banner

Kazia Therapeutics Ltd
F:NV9

Watchlist Manager
Kazia Therapeutics Ltd Logo
Kazia Therapeutics Ltd
F:NV9
Watchlist
Price: 0.7 EUR
Market Cap: €104.7m

Wall St Price Targets

NV9 Price Targets Summary
Kazia Therapeutics Ltd

There are no price targets for NV9.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Kazia Therapeutics Ltd Competitors:
Price Targets
PRQR
ProQR Therapeutics NV
291% Upside
TTD
Trade Desk Inc
100% Upside

Revenue
Forecast

-16% / Year
Past Growth
2 423% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-16% / Year
Past Growth
2 423% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 8 years, the compound annual growth rate for Revenue has been -16%. The projected CAGR for the next 2 years is 2 423%.

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Kazia Therapeutics Ltd

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Operating Income Forecast
is not available for Kazia Therapeutics Ltd

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Kazia Therapeutics Ltd

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is NV9's stock price target?
Not Available

NV9 does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Kazia Therapeutics Ltd?
Projected CAGR
2 423%

Over the last 8 years, the compound annual growth rate for Revenue has been -16%. The projected CAGR for the next 2 years is 2 423%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett